Navigation Links
ARMO BioSciences Initiates Phase 1 Clinical Trial of First-In-Class Cancer Immunotherapy
Date:11/25/2013

REDWOOD CITY, Calif., Nov. 25, 2013 /PRNewswire/ -- ARMO BioSciences, Inc., a clinical-stage biotechnology company, today announced that it initiated the first cohort of patients with advanced solid tumors in a Phase 1 clinical trial of AM0010, a PEGylated form of recombinant human interleukin-10 (IL-10). Based on extensive clinical and preclinical data, ARMO plans to develop this unique molecule for known indications and innovative applications including cancer, fibrosis, hypercholesterolemia/atherosclerosis and inflammatory diseases. 

"Since its founding in December 2012, ARMO raised $20 million in a Series A round, licensed the PEGylated human IL-10 polypeptide from Merck, purchased the Prevascar (rHuIL-10) assets from Renovo Ltd. and assembled an outstanding scientific team with remarkable depth and knowledge of IL-10 to bring AM0010 into the clinic in record time," said Beth Seidenberg, M.D., partner at Kleiner Perkins Caufield & Byers and a member of the ARMO board of directors. "We see enormous potential in the development of this promising molecule."

"Multiple studies have shown that AM0010 directly activates tumor specific CD8+ killer T lymphocytes, which completely eradicate large tumor masses while establishing a lasting anti-tumor immune surveillance and significantly reduce metastatic disease in preclinical models," said Peter Van Vlasselaer, Ph.D., president and chief executive officer of ARMO.  "We expect our exceptional momentum in advancing AM0010 into development to continue, with initiation of additional clinical studies potentially in fibrosis, homozygous familial hypercholesterolemia and other indications in 2014, and anticipate results from our first study as soon as mid-2014."

The Phase 1 clinical trial is designed to establish the safety and tolerability of AM0010 in patients with advanced solid tumors. Ad
'/>"/>

SOURCE ARMO BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
3. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
4. Neurocrine Biosciences Reports First Quarter 2012 Results
5. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
8. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
9. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
10. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
11. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... June 24, 2015 ... addition of the "2015 Strategies in the ... This new 175-page report provides analysis ... diabetes (strips and meters), pregnancy, ovulation, and occult ... regulatory requirements, technologies, and competitive profiles. ...
(Date:7/1/2015)... KONG and FT LAUDERDALE, Florida ... Inc. ("OrbusNeich"), a designer, developer, manufacturer and marketer of innovative ... that on May 13, 2015, it prevailed in a final ... European Patent EP 1 341 482 - STENT HAVING HELICAL ... of review in the EPO and has been upheld as ...
(Date:7/1/2015)... , July 1, 2015 Dynatronics ... manufacturer and marketer of rehabilitation and physical therapy ... $4,025,000 private placement financing led by affiliates of ... equity investor focused on the healthcare industry. The ... organic growth and pursue potential strategic acquisitions.  ...
Breaking Medicine Technology:2015 Strategies in the Home/Self Testing Market 2OrbusNeich Announces Favorable Ruling from the European Patent Office and Initiation of Litigation Against Terumo Corporation 2Dynatronics Announces Completion Of $4,025,000 Private Placement Led By Prettybrook Partners 2Dynatronics Announces Completion Of $4,025,000 Private Placement Led By Prettybrook Partners 3
... Corporation (NYSE: CVS ) today announced that ... repurchase program for up to $4.0 billion of the ... is effective immediately, permits the company to effect the ... open market repurchases, privately negotiated transactions, accelerated share repurchase ...
... Inc. (Pink Sheets: GATA ) announced on August 15, ... are currently processing, and they are expecting this number to increase ... company expects to be able to convert at least two thirds ... The company also stated that due to the ...
Cached Medicine Technology:CVS Caremark Corporation Announces New Share Repurchase Authorization for up to $4 Billion of Common Stock 2CVS Caremark Corporation Announces New Share Repurchase Authorization for up to $4 Billion of Common Stock 3Groupe Athena, Inc. Clarifies Previous Guidance 2Groupe Athena, Inc. Clarifies Previous Guidance 3
(Date:7/1/2015)... , ... July 01, 2015 , ... Dr. Surya Challa ... July 6th on WAVY-TV’s The Hampton Roads Show to discuss non-invasive CoolSculpting . ... and exercise fall short. , CoolSculpting fat reduction utilizes Cryolipolysis to literally freeze ...
(Date:7/1/2015)... ... July 01, 2015 , ... During ... Posey (Manager, National Sales Training and Development) and Chuck Corso (Associate Sales Trainer) ... in Phoenix, AZ. LTEN brings together learning and development professionals from more than ...
(Date:7/1/2015)... ... ... Convoy of Hope will partner with local businesses, churches, government agencies ... at Spring Lake Park High School. , During the celebration, Convoy of Hope and ... and services including free food, health services, family portraits, job services, a carnival and ...
(Date:7/1/2015)... ... July 01, 2015 , ... Element Blue ™, a ... that it has received trademark protection for its SensorInsight® computer software platform. SensorInsight® ... from multiple sources providing an environment where users can view and compare real-time ...
(Date:7/1/2015)... Arizona (PRWEB) , ... July 01, 2015 , ... Amada ... opened a new office in the greater Phoenix area – their Mesa, Arizona ... move to senior care with their purchase of the rights to the area after ...
Breaking Medicine News(10 mins):Health News:Dr. Surya Challa of Chesapeake Vein Center and MedSpa Will be Featured on The Hampton Roads Show on WAVY-TV 2Health News:Dr. Surya Challa of Chesapeake Vein Center and MedSpa Will be Featured on The Hampton Roads Show on WAVY-TV 3Health News:Mission Pharmacal Company: Alamo Pharma Services' Training Leaders Take Steps to Further Expand Capabilities for Mission Pharmacal and Other Clients 2Health News:Mission Pharmacal Company: Alamo Pharma Services' Training Leaders Take Steps to Further Expand Capabilities for Mission Pharmacal and Other Clients 3Health News:Mission Pharmacal Company: Alamo Pharma Services' Training Leaders Take Steps to Further Expand Capabilities for Mission Pharmacal and Other Clients 4Health News:Convoy of Hope Hosts Community Event in the Twin Cities 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 3Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 4Health News:Amada Senior Care Expands to Greater Phoenix Area 2
... has tried to analyze the many reasons why some teen ... with IVF treatments //. In his reading, they are just ... be ridiculed. ,Laurence Shaw, the deputy medical director ... the opinion that, it is the internal program charted by ...
... IT is a general occurrence that people living in ... than those who stay in the opposite //. ... and find a close link and scientific backing to ... societies with better hygiene have higher rates of allergy ...
... suggested by researchers that being exposed to too much ... chance of developing breast tumours //. Women particularly those ... considered to be of particularly risk. ,For ... Cancer Institute and National Institute of Environmental Health Sciences, ...
... a tool used to develop human disease research, now proved ... //complex virus - the vaccinia virus, which is used in ... for Allergy & Immunology (LIAI). ,Researchers at ... have used it to successfully predict immune response to one ...
... destroy viruses due to their protective protein cover which protects ... harmful //. ,Tackling this problem, scientists at the ... of the European Molecular Biology Laboratory (EMBL) in Grenoble have ... of a protein that allows the rabies virus to be ...
... in India open to acting in B'wood Sydney, Sabrina ... represent Australia in the Miss World contest, says she is ... of non-Australian parentage to win the Miss Australia title last ... a Lebanese father. ,Sabrina, who supports a charity ...
Cached Medicine News:Health News:Protected Environment v/s Unprotected Affect Hygiene Health Immunity 2Health News:Protected Environment v/s Unprotected Affect Hygiene Health Immunity 3Health News:Protected Environment v/s Unprotected Affect Hygiene Health Immunity 4Health News:Exposure To Artificial Light Could Be Cancerous 2Health News:Bioinformatics Made a Boon In Immune Response Study - LIAI Finds 2Health News:Bioinformatics Made a Boon In Immune Response Study - LIAI Finds 3
... extensive line of affordable, high-quality light guide ... light sources to provide optimal brightness during ... and durable design give you the flexibility ... efficiently. And each is fully-autoclavable so they ...
Used under fluoroscopy for initial location and positioning of the renal collecting system throughout a percutaneous nephrostomy. Supplied sterile in peel-open packages. Intended for one-time use....
The Linvatec 3mm and 5mm Universal Light Guides are autoclavable. They offer flexibility, superior light transmission, and universal fittings in a lightweight package....
ACMI™ offers an assortment of fiberoptic light guides, high transmission autoclavable fiberoptic light guides, and light guide adapters to connect our scopes to other manufacturers' light sourc...
Medicine Products: